Zobrazeno 1 - 10
of 290
pro vyhledávání: '"Tumour hypoxia"'
Autor:
Alastair McCabe, Stewart Martin, Selene Rowe, Jagrit Shah, Paul S. Morgan, Damian Borys, Rafal Panek
Publikováno v:
European Radiology Experimental, Vol 8, Iss 1, Pp 1-14 (2024)
Abstract Background Tumour hypoxia is a recognised cause of radiotherapy treatment resistance in head and neck squamous cell carcinoma (HNSCC). Current positron emission tomography-based hypoxia imaging techniques are not routinely available in many
Externí odkaz:
https://doaj.org/article/4cdf90cad616462cb95ae643ce3f064e
Autor:
Bingting Li, Jun Zhang, Ning Ma, Weidan Li, Guoxing You, Gan Chen, Lian Zhao, Quan Wang, Hong Zhou
Publikováno v:
Artificial Cells, Nanomedicine, and Biotechnology, Vol 51, Iss 1, Pp 120-130 (2023)
AbstractDoxorubicin (DOX) is an effective chemotherapeutic agent widely used for cancer treatment. However, hypoxia in tumour tissue and obvious adverse effects particularly cardiotoxicity restricts the clinical usage of DOX. Our study is based on th
Externí odkaz:
https://doaj.org/article/c6cffe8d3b3940c889765348a38f8f5e
Autor:
Mohammad Zahedi, Hanieh Salmani Izadi, Faezeh Arghidash, Eric Gumpricht, Maciej Banach, Amirhossein Sahebkar
Publikováno v:
Archives of Medical Science, Vol 19, Iss 6, Pp 1616-1629 (2023)
Hypoxia can lead to different responses from cancer cells, including cell death or survival, partially depending on how long it is exposed. Patients with cancer and under hypoxic tumour conditions have a poorer prognosis and are at greater risk of me
Externí odkaz:
https://doaj.org/article/b359337a1ae649ad8ba011e55ba7e272
Autor:
Matthew Fok, Rhianna Hill, Hayley Fowler, Rachael Clifford, Aaron Kler, Jayanma Uzzi-Daniel, Sonia Rocha, Gabrielle Grundy, Jason Parsons, Dale Vimalachandran
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 44, Iss , Pp 100695- (2024)
Introduction: Neoadjuvant radiotherapy is successfully used in rectal cancer to improve overall survival. However, treatment response is both unpredictable and variable. There is strong evidence to show that the phenomenon of tumour hypoxia is associ
Externí odkaz:
https://doaj.org/article/05c15f1c8f4a4c4186458900566e0667
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Pauline Bourigault, Michael Skwarski, Ruth E. Macpherson, Geoff S. Higgins, Daniel R. McGowan
Publikováno v:
EJNMMI Research, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Background Tumour hypoxia promotes an aggressive tumour phenotype and enhances resistance to anticancer treatments. Following the recent observation that the mitochondrial inhibitor atovaquone increases tumour oxygenation in NSCLC, we sought
Externí odkaz:
https://doaj.org/article/9bfbefdd4c21420098f64b08bbfadcbc
Autor:
Zhongwen Yang, Changsong Shi, Dongliang Cheng, Yu Wang, Yan Xing, Fanfan Du, Fangfang Wu, Yao Jin, Yueli Dong, Mengli Li
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Hypoxia, as a typical hallmark of the tumour microenvironment (TME), has been verified to exist in most malignancies and greatly hinders the outcome of tumour treatments, including chemotherapy, photodynamic therapy, radiotherapy, and immunotherapy.
Externí odkaz:
https://doaj.org/article/177f43653b544045b23c1771cf9779b2
Publikováno v:
Pharmaceuticals, Vol 16, Iss 9, p 1276 (2023)
When developing novel radiopharmaceuticals, a linker moiety between the chelator and targeting vector can have a crucial influence on adjusting the affinity of the tracer and its biodistribution in organisms. To develop novel 99mTc-labelled hypoxia i
Externí odkaz:
https://doaj.org/article/6a52042aff204cdbb3420827338c2dbd
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.